Physician profile
Seth Ray Hendrix
NPI 1821499823
$12,294.50
in general payments reported to CMS, 2019-2025
27 companies · $2,609 in 2025
The $2,609 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,589 · 2022: $2,549 · 2023: $2,049 · 2024: $2,498 · 2025: $2,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,096 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,096.12 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,225.26 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,652.75 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,207.78 | 2021-2025 | |
| Janssen Biotech, INC. | $835.31 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $834.08 | 2021-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $573.47 | 2022-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $290.09 | 2024-2025 | Orencia |
| Lilly USA, LLC | $198.79 | 2021-2024 | Taltz |
| Pfizer INC. | $196.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $163.02 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $139.82 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $137.04 | 2021-2025 | Tymlos |
| Pacira Therapeutics, INC. | $128.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.27 | 2021-2025 | Cyltezo |
| Genzyme Corporation | $119.57 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $116.24 | 2023-2025 | Saphnelo |
| Genentech USA, INC. | $102.01 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $64.05 | 2024-2025 | Purified Cortrophin Gel |
| Organon LLC | $46.01 | 2025 | Hadlima, Renflexis, Nexplanon |
| Invivyd INC | $21.58 | 2025 | Pemgarda |
| Alvogen INC | $21.22 | 2025 | Teriparatide |
| Almatica Pharma LLC | $20.60 | 2024 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $16.93 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $16.60 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.16 | 2024 | Truxima |
| Alexion Pharmaceuticals, INC. | $14.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.